Cocrystal Pharma, Inc.
Business
Cocrystal Pharma is a clinical-stage biotechnology company discovering and developing small-molecule antiviral therapeutics targeting RNA viruses including influenza, coronavirus, norovirus, and hepatitis C. The company employs proprietary structure-based drug design technology utilizing cocrystal X-ray crystallography and computational chemistry. Its pipeline includes CC-42344 for influenza A in Phase 2a, CDI-988 for norovirus and coronavirus in Phase 1b, and CC-31244 for hepatitis C.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 5 | 13 | 15 | 12 | 9 | |
| General and administrative | 4 | 5 | 6 | 6 | 5 | |
| Total operating expenses | 9 | 18 | 19 | 39 | 14 | |
| Loss from operations | −9 | −18 | −19 | −39 | −14 | |
| Interest income, net | 134,000 | 537,000 | 640,000 | — | — | |
| Foreign exchange gain (loss) | 54,000 | −163,000 | −65,000 | −18,000 | −9,000 | |
| Total other income, net | 188,000 | 374,000 | 575,000 | −8,000 | 36,000 | |
| Net loss | −9 | −18 | −18 | −39 | −14 | |
| Net loss per common share, basic | −0.78 | −1.72 | −1.87 | −4.77 | −0.16 | |
| Net loss per common share, diluted | −0.78 | −1.72 | −1.87 | −4.77 | — | |
| Weighted average number of common shares outstanding, basic | 11 | 10 | 10 | 8 | 7 | |
| Weighted average number of common shares outstanding, diluted | 11 | 10 | 10 | 8 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 7 | 10 | 26 | 37 | 59 | |
| Restricted cash | 75,000 | 75,000 | 75,000 | 75,000 | 50,000 | |
| Tax credit receivable | 706,000 | 1 | 890,000 | 716,000 | — | |
| Prepaid expenses and other current assets | 328,000 | 430,000 | 2 | 2 | 568,000 | |
| Total current assets | 8 | 12 | 29 | 40 | 59 | |
| Property and equipment, net | 93,000 | 153,000 | 271,000 | 342,000 | 453,000 | |
| Deposits | 95,000 | 29,000 | 46,000 | 46,000 | 46,000 | |
| Operating lease right-of-use assets, net (including $152 and $42 to related party) | 1 | 2 | 2 | 274,000 | 478,000 | |
| Total assets | 10 | 13 | 31 | 41 | 79 | |
| Accounts payable and accrued expenses | 2 | 2 | 3 | 976,000 | 1 | |
| Current maturities of operating lease liabilities (including $49 and $42 to related party) | 334,000 | 301,000 | 240,000 | 233,000 | 209,000 | |
| Total current liabilities | 2 | 2 | 3 | 1 | 2 | |
| Operating lease liabilities (including $104 and $0 to related party) | 1 | 2 | 2 | 57,000 | 291,000 | |
| Total long-term liabilities | 1 | 2 | 2 | 57,000 | 298,000 | |
| Total liabilities | 3 | 4 | 5 | 1 | 2 | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock $0.001 par value; 100,000 and 150,000 shares authorized as of December 31, 2025 and 2024, respectively; 13,784 and 10,174 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 13,000 | 10,000 | 10,000 | 8,000 | 8,000 | |
| Additional paid-in capital | 349 | 343 | 342 | 337 | 337 | |
| Accumulated deficit | −342 | −333 | −316 | −298 | −259 | |
| Total stockholders equity | 6 | 10 | 26 | 40 | 78 | |
| Total liabilities and stockholders equity | 10 | 13 | 31 | 41 | 79 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization expense | 72,000 | 126,000 | 189,000 | 185,000 | 190,000 | |
| Right of use assets | 304,000 | 320,000 | −2 | 203,000 | — | |
| Stock-based compensation | 270,000 | 643,000 | 801,000 | 855,000 | 724,000 | |
| Change in operating lease liabilities | −301,000 | −210,000 | 2 | −209,000 | — | |
| Tax credit receivable | 509,000 | −325,000 | −174,000 | — | — | |
| Prepaid expenses and other current assets | 102,000 | 1 | 470,000 | −2 | −169,000 | |
| Deposits | −66,000 | 17,000 | — | — | — | |
| Accounts payable and accrued expenses | −251,000 | −895,000 | 2 | −321,000 | −217,000 | |
| Net cash used in operating activities | −8 | −16 | −15 | −21 | −13 | |
| Purchases of property and equipment | −12,000 | −8,000 | −118,000 | −74,000 | −52,000 | |
| Net cash used in investing activities | −12,000 | −8,000 | −118,000 | −74,000 | −52,000 | |
| Proceeds from the sale of common stock under ATM | 154,000 | — | 4 | — | 39 | |
| Proceeds from sale of common stock and warrants, net of transaction costs | 5 | — | — | — | — | |
| Net cash provided by financing activities | 5 | — | 4 | −27,000 | 38 | |
| Net decrease in cash and restricted cash | −3 | −16 | −11 | −22 | 26 | |
| Initial recognition of right-of-use assets and lease liabilities | — | 163,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cocrystal Pharma, Inc.'s CIK number?
Cocrystal Pharma, Inc.'s SEC CIK number is 0001412486 (1412486). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cocrystal Pharma, Inc.'s SEC filings?
All of Cocrystal Pharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Cocrystal Pharma, Inc. last report earnings?
Cocrystal Pharma, Inc. (COCP) most recently filed an earnings 8-K with the SEC on Mar 31, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-013837). This is Cocrystal Pharma, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Cocrystal Pharma, Inc.'s most recent earnings 8-K?
Cocrystal Pharma, Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 31, 2026 under accession 0001493152-26-013837. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Cocrystal Pharma, Inc.'s latest earnings 8-K →
Look up any company's CIK number →